Moderna (MRNA) Other Non-Current Assets (2017 - 2026)
Moderna (MRNA) posted quarterly Other Non-Current Assets of $618.0 million for Q2 2026, up 13.19% year-over-year from $546.0 million in Q2 2025, and down 8.44% on a QoQ basis from $675.0 million in Q1 2026.
Moderna (MRNA) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Moderna has reported Other Non-Current Assets for 10 years, with the latest figure at $618.0 million in Q2 2026.
- Other Non-Current Assets for Q2 2026 came in at $618.0 million, up 13.19% year-over-year; the trailing twelve-month figure through Jun 2026 was $618.0 million (up 13.19% YoY), and the FY2025 annual result was $605.0 million, up 1.85% from the prior year.
- Other Non-Current Assets eased to $618.0 million in Q2 2026, from $675.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.3 billion in Q2 2023 and troughed at $38.0 million in Q3 2022.
- A 5-year average of $613.1 million and a median of $611.5 million in 2025 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2022, when Other Non-Current Assets jumped 2047.83%; it then plunged 50.31% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $988.0 million in 2022, then retreated by 22.47% to $766.0 million in 2023, then decreased by 22.45% to $594.0 million in 2024, then advanced by 1.85% to $605.0 million in 2025, then grew by 2.15% to $618.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $618.0 million in Q2 2026, $675.0 million in Q1 2026, and $605.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 618.00 Mn |
| Mar 31, 2026 | 675.00 Mn |
| Dec 31, 2025 | 605.00 Mn |
| Sep 30, 2025 | 530.00 Mn |
| Jun 30, 2025 | 546.00 Mn |
| Mar 31, 2025 | 556.00 Mn |
| Dec 31, 2024 | 594.00 Mn |
| Sep 30, 2024 | 556.00 Mn |
| Jun 30, 2024 | 641.00 Mn |
| Mar 31, 2024 | 650.00 Mn |
| Dec 31, 2023 | 766.00 Mn |
| Sep 30, 2023 | 661.00 Mn |
| Jun 30, 2023 | 1.29 Bn |
| Mar 31, 2023 | 1.16 Bn |
| Dec 31, 2022 | 988.00 Mn |
| Sep 30, 2022 | 14.00 Mn |
| Jun 30, 2022 | 75.00 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 46.00 Mn |
| Sep 30, 2021 | 11.00 Mn |